Neurocrine Biosciences | NBIX - Market Capitalization

Stock Price
158.42
Daily Change
-0.63 -0.40%
Monthly
23.37%
Yearly
30.90%
Q2 Forecast
155.24

Neurocrine Biosciences reported $15.83B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 364.22B 20.46B May/2026
Acadia Pharmaceuticals USD 3.57B 221M May/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
ALKERMES USD 5.66B 217M May/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amgen USD 189.89B 13.64B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.18B 683M May/2026
Cytokinetics USD 9.16B 975M May/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Exelixis USD 14.34B 3.44B May/2026
Gilead Sciences USD 167.39B 5.6B May/2026
Halozyme Therapeutics USD 8.44B 781M May/2026
Incyte USD 21.73B 3B May/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Nektar Therapeutics USD 15.62B 14.76B May/2026
Neurocrine Biosciences USD 15.15B 1.9B May/2026
Pfizer USD 147.4B 6.42B May/2026
Prothena USD 514M 11M Dec/2025
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Repligen USD 7.01B 360M May/2026
Sarepta Therapeutics USD 2.16B 123M May/2026
Teva Pharmaceutical Industries USD 34.27B 2.14B Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 1000K May/2026
Vertex Pharmaceuticals USD 113.58B 1000K May/2026